This contract is to advance the development of romiplostim for treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT) and a drug…

Active Definitive Contract Awarded Last action

Contract number
75A50119C00061
Awardee
Awarding agency
Obligated
$26,408,674

Award facts

Opportunity
Contract value 78% obligated
  • $26,408,674.24 Current, with exercised options
  • $33,719,968.24 Potential, with all options
Completion date 86% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Thousand Oaks, CA 91320, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00005 · Supplemental funding for $3,711,014.00 to clin 002, DE-OB $1,434,722.76 in canceling funds under OS241378, add julie bergmann to the contract as an alternate… $2,276,291
Other Administrative Action P00004 · No cost modification to revise the POP within prism to match bilateral modification dates. $0
Other Administrative Action P00003 · No cost modification to revise the POP for clin 0006 option 4 $0
Funding Only Action P00002 · Amgen INC - supplemental funding for clin 0001, base award. $475,000
Exercise an Option P00001 · Exercise option 4 clin 0006 device feasibility (self administration kit), revise the contracting officer, additional far clauses included in full text was… $2,193,840
Original award $21,463,543

About this award

Written by GovTribe AI ·

This contract awarded to Amgen Inc. by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) provides $33,719,968.24 to advance the development of romiplostim for the treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT), as well as a drug delivery device feasibility project. The contract includes a $3,711,014.00 supplement to CLIN 002 and the de-obligation of $1,434,722.76 in canceling funds under OS241378. The award has an ultimate completion date of December 31, 2027 and does not utilize a set-aside. This contract is related to a Broad Agency Announcement from BARDA seeking proposals to develop medical countermeasures against chemical, biological, radiological, nuclear and pandemic influenza threats.

Description

As the agency reported it.

This contract is to advance the development of romiplostim for treatment of hematopoietic subsyndrome-acute radiation syndrome (HS-ARS) and chemotherapy-induced thrombocytopenia (CIT) and a drug delivery device feasibility project with an option to

Quick answers

Who was awarded contract 75A50119C00061?

75A50119C00061 was awarded to Amgen Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 26, 2019.

How much is contract 75A50119C00061 worth?

The government has obligated $26,408,674 on 75A50119C00061. Its potential value, with all options, is $33,719,968.

Was contract 75A50119C00061 competed?

The extent of competition for 75A50119C00061 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login